19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Recent studies are lacking reports on mortality after non-hip fractures in adults aged > 65.

          Methods

          This retrospective, matched-cohort study used de-identified health services data from the publicly funded healthcare system in Ontario, Canada, contained in the ICES Data Repository. Patients aged 66 years and older with an index fragility fracture occurring at any osteoporotic site between 2011 and 2015 were identified from acute hospital admissions, emergency and ambulatory care using International Classification of Diseases (ICD)-10 codes and data were analyzed until 2017. Thus, follow-up ranged from 2 years to 6 years. Patients were excluded if they presented with an index fracture occurring at a non-osteoporotic fracture site, their index fracture was associated with a trauma code, or they experienced a previous fracture within 5 years prior to their index fracture. This fracture cohort was matched 1:1 to controls within a non-fracture cohort by date, sex, age, geography and comorbidities. All-cause mortality risk was assessed.

          Results

          The survival probability for up to 6 years post-fracture was significantly reduced for the fracture cohort vs matched non-fracture controls ( p < 0.0001; n = 101,773 per cohort), with the sharpest decline occurring within the first-year post-fracture. Crude relative risk of mortality (95% confidence interval) within 1-year post-fracture was 2.47 (2.38–2.56) in women and 3.22 (3.06–3.40) in men. In the fracture vs non-fracture cohort, the absolute mortality risk within one year after a fragility fracture occurring at any site was 12.5% vs 5.1% in women and 19.5% vs 6.0% in men. The absolute mortality risk within one year after a fragility fracture occurring at a non-hip vs hip site was 9.4% vs 21.5% in women and 14.4% vs 32.3% in men.

          Conclusions

          In this real-world cohort aged > 65 years, a fragility fracture occurring at any site was associated with reduced survival for up to 6 years post-fracture. The greatest reduction in survival occurred within the first-year post-fracture, where mortality risk more than doubled and deaths were observed in 1 in 11 women and 1 in 7 men following a non-hip fracture and in 1 in 5 women and 1 in 3 men following a hip fracture.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12891-021-03960-z.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Osteoporosis

          Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high or imminent risk of fracture, therapy with teriparatide or abaloparatide should be considered; however, since treatment duration with these drugs is restricted to 18-24 months, treatment should be continued with an antiresorptive drug. Individuals at high risk of fractures do not receive adequate treatment and strategies to address this treatment gap-eg, widespread implementation of Fracture Liaison Services and improvement of adherence to therapy-are important challenges for the future.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            European guidance for the diagnosis and management of osteoporosis in postmenopausal women

            Summary Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2013. This manuscript updates these in a European setting. Methods Systematic reviews were updated. Results The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk; general and pharmacological management of osteoporosis; monitoring of treatment; assessment of fracture risk; case-finding strategies; investigation of patients; health economics of treatment. The update includes new information on the evaluation of bone microstructure evaluation in facture risk assessment, the role of FRAX® and Fracture Liaison Services in secondary fracture prevention, long-term effects on fracture risk of dietary intakes, and increased fracture risk on stopping drug treatment. Conclusions A platform is provided on which specific guidelines can be developed for national use.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

                Bookmark

                Author and article information

                Contributors
                lslatkov@amgen.com
                Journal
                BMC Musculoskelet Disord
                BMC Musculoskelet Disord
                BMC Musculoskeletal Disorders
                BioMed Central (London )
                1471-2474
                23 January 2021
                23 January 2021
                2021
                : 22
                : 105
                Affiliations
                [1 ]GRID grid.411081.d, ISNI 0000 0000 9471 1794, CHU de Québec Research Centre and Laval University, ; Québec, QC Canada
                [2 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Medicine, , McMaster University, ; Hamilton, ON Canada
                [3 ]GRID grid.39381.30, ISNI 0000 0004 1936 8884, Division of Orthopaedic Surgery, , Western University, ; London, ON Canada
                [4 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Health Research Methods, Evidence and Impact (HEI), , McMaster University, ; Hamilton, ON Canada
                [5 ]GRID grid.416721.7, ISNI 0000 0001 0742 7355, Programs for Assessment of Technology in Health, The Research Institute of St. Joe’s Hamilton, St Joseph’s Healthcare Hamilton, ; Hamilton, ON Canada
                [6 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Centre for Health Economics and Policy Analysis (CHEPA), , McMaster University, ; Hamilton, ON Canada
                [7 ]GRID grid.17063.33, ISNI 0000 0001 2157 2938, Department of Family and Community Medicine, , University of Toronto, ; Toronto, Canada
                [8 ]GRID grid.417886.4, ISNI 0000 0001 0657 5612, Amgen Inc, ; California, USA
                [9 ]GRID grid.417979.5, ISNI 0000 0004 0538 2941, Amgen Canada Inc., ; Toronto, Canada
                Author information
                http://orcid.org/0000-0001-5027-7989
                Article
                3960
                10.1186/s12891-021-03960-z
                7824940
                33485305
                fdd94516-9f48-4818-81df-fa9bffed9f21
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 15 May 2020
                : 5 January 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100010875, Amgen Canada;
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2021

                Orthopedics
                fracture,osteoporosis,mortality,real-world,older adults
                Orthopedics
                fracture, osteoporosis, mortality, real-world, older adults

                Comments

                Comment on this article